Peter Attia & Outlive: A European Take

Peter Attia is a US physician (Johns Hopkins, Stanford) and one of the most influential voices in longevity. His 2023 book "Outlive: The Science and Art of Longevity" was a bestseller. It shapes a lot of how people think about long healthy living today.

Attia runs a private practice in the US. His patient list is tiny and very wealthy. That splits opinions: he reads the evidence carefully, but his style of care is priced out of reach for almost everyone.

His real value for the rest of us sits in the mental models. Outlive gives you clean ways to think about healthspan versus lifespan. It also gives you better questions to bring to your own doctor.

Attia's main point: most early deaths (before age 85) come from four clusters of disease.

1. Atherosclerotic cardiovascular disease (ASCVD), meaning heart attack and stroke. It is the top cause of death in Germany. Attia's move: start intervening very early, guided by markers like lipoprotein(a), ApoB, LDL-C, and hsCRP.

2. Cancer. Catch it earlier: colonoscopy from 40 is Attia's private-practice recommendation, not a guideline. For comparison, USPSTF recommends starting at 45. Since 1 April 2025 (G-BA Beschluss vom 16.01.2025), German GKV covers screening colonoscopy equally for men and women from age 50. Going earlier than the GKV baseline is a self-pay private choice. Regular skin checks, and whole-body MRI if you are at higher risk. How well this works is debated. More tests also mean more false alarms.

3. Neurodegenerative disease, such as Alzheimer's, Parkinson's, and dementia. Focus on heart and blood vessel health, mental stimulation, social contact, sleep, and training.

4. Metabolic dysfunction, meaning type 2 diabetes, fatty liver, and metabolic syndrome. Strong focus on insulin sensitivity, belly fat around the organs, and how your body handles sugar.

For the average patient, the concepts are useful. The intensity of Attia's screening plan is not realistic, and for low-risk people it is not strongly backed by evidence either.

Attia splits medicine into three eras.

Medicine 1.0: folk medicine and simple observation, up to about the mid-1800s (Medicine 2.0 begins with germ theory — Pasteur, Koch, Snow).

Medicine 2.0: today's evidence-based medicine. You get a diagnosis once symptoms show up. Treatment relies on randomised trials. It works, but it mostly reacts.

Medicine 3.0: Attia's proposed next step. Prevention before treatment. Risk sorted out for each person individually. Healthspan as the goal. The patient as an active partner.

For the German system, this overlaps with Vorsorge (the preventive check-ups covered by GKV statutory insurance). But Medicine 3.0 at Attia's intensity is mostly a self-pay affair, or something you find in specialised private clinics (see our self-pay guide).

This is one of the most useful ideas in Outlive: write down what you want to physically be able to do during your Marginal Decade — Attia's term for the final ten years of your life, whenever those arrive. Age 90 is a reasonable planning proxy, but the concept is about the quality of that last decade, not a fixed calendar age.

Attia's version: list 10 physical capacities. The canonical examples Attia uses in Outlive (Ch. 12) are mostly functional rather than athletic:

• Hike 1.5 miles on a hilly trail
• Get up off the floor with one arm (ideally no hands)
• Pick up a young child off the floor (Attia in interviews specifies ~14 kg / 30 lb)
• Carry two ~2.3 kg (5 lb) bags of groceries for five blocks
• Lift a ~9 kg (20 lb) suitcase into an overhead bin
• Balance on one leg with eyes open for 30 seconds
• Have sex
• Climb four flights of stairs in three minutes
• Open a jar
• Do 30 consecutive jump-rope skips

The list is deliberately personal — pick the capacities that matter to you.

The point: physical performance fades with age. To still hit these in your Marginal Decade, you need to be able to do clearly more today. Attia does not use a blanket "double at 50" rule — that is a shorthand. In Outlive he back-calculates from known age-related decline curves that differ by capacity: VO2 max drops roughly 10 % per decade (and faster after 50-60), while muscle strength and power decline at their own rates. You plan backward from your Marginal Decade target along the curve for each capacity — sometimes that is roughly double today, sometimes more, sometimes less. For VO2 max specifically, Attia's longevity benchmark is the "elite" tier (top ~2.5% in the Mandsager 2018 cardiorespiratory-fitness data he cites) — and he has repeatedly framed the goal as reaching the elite cut-off for someone roughly two decades younger (paraphrased from Outlive and his Drive podcast episodes on VO2 max).

Training priorities fall out of that: strength, stability, Zone 2 aerobic efficiency, and VO2 max. The weekly structure Attia repeatedly recommends: about 3 hours of Zone 2 cardio per week as a patient floor, with 3-4 hours per week (in sessions of ≥45 minutes) as his personal target. Plus one 4x4 VO2 max session — four rounds of four minutes hard, three minutes easy active recovery (Helgerud's Norwegian protocol). Plus 2-3 strength sessions. Not isolated muscle size. Not marathon times.

You can use Attia's framework at three levels of effort.

Free or low effort:

• Do the Centenarian Decathlon exercise. Write down your 10 capacities.
• Aim your training at those targets (strength, Zone 2 cardio, HIIT, mobility)
• Use the GKV Vorsorge you already have (from age 35, every 3 years)

Medium effort (self-pay):

• Expanded blood panel with ApoB, Lp(a), hsCRP, HbA1c, fasting insulin (about 100 to 250 euros)
• VO2 max test at a sports-medicine clinic (100 to 200 euros)
• DEXA scan (50 to 120 euros) for bone and body composition
• Carotid intima-media measurement (70 to 150 euros)
• A private longevity consult (150 to 400 euros per visit)

High effort (benefit debated):

• Whole-body MRI (800 to 2,500 euros). For low-risk patients, false alarms often outweigh the upside.
• CGM (continuous glucose monitor) without diabetes (50 to 150 euros per month)
• Coronary calcium score (150 to 300 euros)

Attia's core lesson is free: picture your life at 85 and plan backwards from there. It is the single most valuable tool in the whole book.

Your 12 months on the Attia framework

A realistic DACH monthly roadmap:

• Month 1: write your own Centenarian Decathlon (10 capacities for your Marginal Decade). No spending.
• Month 2: book GKV Vorsorge (free, ages 35+ every 3 years) plus a fasting lipid panel.
• Month 3: IGeL expansion — ApoB, Lp(a), hsCRP, fasting insulin (~€100-250 at Synlab, Limbach, Lademannbogen, or IMD Berlin). Lp(a) is a one-time lifetime test.
• Month 6: VO2 max test at a sports-medicine Praxis (€100-200) plus DEXA (€50-120).
• Month 9: coronary calcium score if indicated by your cardiovascular risk profile (~€150-300).
• Month 12: repeat the Decathlon exercise and compare your lifts, VO2 max, and ApoB to baseline. Adjust training block.

Decathlon targets by decade

A practical shorthand scaling relative to your Marginal Decade target. Attia himself back-calculates from capacity-specific decline curves rather than a single multiplier, so treat these as planning approximations:

• At 50: aim for roughly 2x the Marginal Decade target
• At 60: roughly 1.5x
• At 70: roughly 1.2x
• VO2 max: aim for the "elite" tier at your current age (top ~2.5% in Mandsager 2018, the data Attia cites); he has repeatedly framed the goal as reaching the elite cut-off for someone two decades younger — consistent with ~10% decline per decade toward your Marginal Decade floor
• Grip strength: ~40 kg (men) / ~27 kg (women) are PURE/DEGS mid-life population averages sometimes used as functional aspirational targets — they are not guideline-defined minimums. The EWGSOP2 sarcopenia cut-offs are much lower (<27 kg men, <16 kg women); falling below those flags clinical sarcopenia, while the population-average figures are simply where the median adult sits

Four Horsemen through a female lens

The Four Horsemen apply to women too, but the weighting shifts after menopause. Cardiovascular risk accelerates with estrogen loss; preeclampsia history ≈ 2x future CHD risk (see women's guide). Alzheimer's hits women disproportionately, partly for biological reasons. ApoB and Lp(a) matter just as much; so does early DEXA screening from 50 for osteoporosis.

Rapamycin in Attia's practice (honest note)

Attia has publicly discussed using rapamycin off-label for several years and has also discussed pausing or reducing his own use through 2023–2024 (mouth sores, uncertain benefit signals). Late-2025 podcast/AMA discussion suggests a more definitive pause; verify against The Drive episodes from October–November 2025 if a current status is needed. The PEARL trial read-out in late 2024 did not meet its primary endpoint of visceral adiposity reduction. A sex-stratified subgroup analysis (not pre-powered) flagged positive signals on lean mass and self-reported pain in women on the 10 mg/week arm — treat these as hypothesis-generating, not as confirmed effects. His current public position is cautious. See rapamycin guide.